Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27
Related Experiment Video
Updated: Oct 27, 2026

12:25
Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells
Published on: July 21, 2026
F Asanuma1, Y Yamada, E Kawamura
1Department of Surgery, Kitasato Institute Hospital, Tokyo, Japan.
Folia Microbiologica
|November 20, 1998
Abstract:
The antitumor effect of paclitaxel, epirubicin, and both in combination was tested using R-27, an estrogen receptor-positive human breast carcinoma. In an in vivo study using nude mice both drugs showed an additive effect, whereas they showed a supraadditive pattern in in vitro MTT assay. The combination of paclitaxel and epirubicin may enhance the antitumor effect on breast carcinoma.
